Francesco Grossi

机构：University of Insubria, Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Azienda Ospedaliera S.Maria, Centre de Recherche en Cancérologie de Lyon, Ospedale Policlinico San Martino, Onco Lille, OncoThAI, CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers, Varian Medical Systems (United States) · ORCID：0000-0001-8412-3136

发表论文 713 篇 · 总被引 22721 次 · h-index 59

代表论文

• Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 (2026 · Journal of Clinical Oncology · 被引 5)
• Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 (2026 · Journal of Clinical Oncology)
• PATHOLOGICAL RESPONSE AFTER NEOADJUVANT THERAPY IN SOFT TISSUE SARCOMA: A SYSTEMATIC REVIEW OF ITS ASSOCIATION WITH LOCAL RECURRENCE, DISTANT METASTASIS, AND SURVIVAL (2026 · European Journal of Surgical Oncology)
• EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study) (2026 · The Oncologist)
• Reply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodologic Fragility and Censoring Bias in the 5-Year Update of CheckMate 743” (2026 · Journal of Clinical Oncology)
• Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 (2026 · Journal of Clinical Oncology)